Merck and Bayer's heart drug meets main goal of late-stage study


Nov 18 (Reuters) - Merck & Co Inc BAYGn.DE for patients with worsening chronic heart failure met the main goal of a late-stage study.

The drug, vericiguat, reduced the risk of heart failure and hospitalization in patients with worsening chronic heart failure compared to placebo, when given in combination with available therapies for the condition, Merck said.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Maju Samuel)

((; within the U.S. +1 646 223 8780, outside the U.S. +91 80 6749 1692;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.